Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

bionorica se - suhi ekstrakt plodu navadne konopljike - filmsko obložena tableta - suhi ekstrakt plodu navadne konopljike 10 mg / 1 tableta - plod navadne konopljike

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

bionorica se - suhi ekstrakt plodu navadne konopljike - filmsko obložena tableta - suhi ekstrakt plodu navadne konopljike 10 mg / 1 tableta - plod navadne konopljike

Evropska unija - slovenščina - EMA (European Medicines Agency)

nabriva therapeutics ireland dac - lefamulin acetate - pneumonia, bacterial; community-acquired infections - antibacterials za sistemsko uporabo, - xenleta is indicated for the treatment of community-acquired pneumonia (cap) in adults when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of cap or when these have failed. upoštevati je treba uradne smernice za ustrezno uporabo protibakterijsko agenti.

Evropska unija - slovenščina - EMA (European Medicines Agency)

aimmune therapeutics ireland limited - defatted powder of arachis hypogaea l., semen (peanuts) - peanut hypersensitivity - allergens - palforzia is indicated for the treatment of patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy. palforzia may be continued in patients 18 years of age and older. palforzia should be used in conjunction with a peanut-avoidant diet.

Evropska unija - slovenščina - EMA (European Medicines Agency)

rhythm pharmaceuticals netherlands b.v. - setmelanotide - debelost - preparati za zaščito proti sončenju, prehrambeni izdelki - imcivree is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed bardet biedl syndrome (bbs), loss-of-function biallelic pro-opiomelanocortin (pomc), including pcsk1, deficiency or biallelic leptin receptor (lepr) deficiency in adults and children 6 years of age and above.

Evropska unija - slovenščina - EMA (European Medicines Agency)

biomarin international limited - vosoritide - achondroplasia - zdravila za zdravljenje bolezni kosti - voxzogo is indicated for the treatment of achondroplasia in patients 4 months of age and older whose epiphyses are not closed. the diagnosis of achondroplasia should be confirmed by appropriate genetic testing.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

zel navadne tavžentrože; korenina luštreka; list navadnega rožmarina - obložena tableta - zel navadne tavžentrože 36 mg / 1 tableta  korenina luštreka36 mg / 1 tableta  list navadnega rožmarina36 mg / 1 tableta; korenina luštreka 36 mg / 1 tableta  list navadnega rožmarina36 mg / 1 tableta; list navadnega rožmarina 36 mg / 1 tableta - drugi urologiki

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

zel navadne tavžentrože; korenina luštreka; list navadnega rožmarina - obložena tableta - zel navadne tavžentrože 36 mg / 1 tableta  korenina luštreka36 mg / 1 tableta  list navadnega rožmarina36 mg / 1 tableta; korenina luštreka 36 mg / 1 tableta  list navadnega rožmarina36 mg / 1 tableta; list navadnega rožmarina 36 mg / 1 tableta - drugi urologiki

Evropska unija - slovenščina - EMA (European Medicines Agency)

bial portela & companhia s.a. - opikapon - parkinsonova bolezen - anti-parkinsonska zdravila - ontilyv is indicated as adjunctive therapy to preparations of levodopa/ dopa decarboxylase inhibitors (ddci) in adult patients with parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.

Evropska unija - slovenščina - EMA (European Medicines Agency)

eigerbio europe limited - lonafarnib - progeria; laminopathies - drugi zdravljene bolezni prebavil in presnove izdelki, - zokinvy is indicated for the treatment of patients 12 months of age and older with a genetically confirmed diagnosis of hutchinson-gilford progeria syndrome or a processing-deficient progeroid laminopathy associated with either a heterozygous lmna mutation with progerin-like protein accumulation or a homozygous or compound heterozygous zmpste24 mutation.